<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347422</url>
  </required_header>
  <id_info>
    <org_study_id>BIVV009-04</org_study_id>
    <secondary_id>2017-003539-12</secondary_id>
    <secondary_id>BIVV009-04</secondary_id>
    <nct_id>NCT03347422</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of BIVV009 in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza Study)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioverativ Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioverativ Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of Part A is to determine whether BIVV009 administration results in a greater
      than or equal to (&gt;=)1.5 gram per deciliter (g/dL) increase in hemoglobin (Hgb) level and
      avoidance of transfusion in participants with primary cold agglutinin disease (CAgD) without
      a recent history of blood transfusion. The purpose of Part B is to evaluate the long-term
      safety and tolerability of BIVV009 in participants with primary CAgD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Percentage of Participants With Response (R)</measure>
    <time_frame>Up to Week 26</time_frame>
    <description>A participant will be considered a responder if he or she did not receive a blood transfusion from Week 5 through Week 26 (EOT) and did not receive treatment for primary cold agglutinin disease (CAgD) beyond what is permitted per protocol. Additionally, the participant's hemoglobin (Hgb) level must meet the following criterion: Hgb increase greater than or equal to (&gt;=) 1.5 gram per deciliter (g/dL) from baseline (defined as the last Hgb value before administration of the first dose of study drug) at treatment assessment endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Mean Change From Baseline in Hemoglobin (Hgb) Level up to Week 26</measure>
    <time_frame>Baseline Up to Week 26</time_frame>
    <description>Mean change from baseline in hemoglobin (Hgb) level up to Week 26 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Mean Change From Baseline in Bilirubin up to Week 26</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Mean change from baseline in bilirubin up to Week 26 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score (Quality of Life)</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>FACIT-Fatigue scale consists of 13 questions assessed using a 5 point scale (0=not at all; 1 = a little bit, 2 = somewhat, 3 = quite a bit and 4 = very much). Responses to each question are added to obtain a total score. The range of possible scores is 0-52, with higher score indicating more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Mean Change From Baseline in Lactate Dehydrogenase (LDH) up to Week 26</measure>
    <time_frame>Baseline up to Week 26</time_frame>
    <description>Mean change from baseline in LDH up to Week 26 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Percentage of Participants With Solicited Symptomatic Anemia at End of Treatment (EOT)</measure>
    <time_frame>At EOT (Day 182)</time_frame>
    <description>Symptomatic anemia is defined as fatigue, weakness, shortness of breath, palpitations, fast heart beat, light headedness, and/or chest pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Agglutinin Disease, Cold</condition>
  <arm_group>
    <arm_group_label>Part A: BIVV009 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A, participants will be randomized 1:1 to receive an intravenous (IV) infusion of BIVV009 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Response Extension Phase (BIVV009)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part B, all participants will undergo blinded cross-over loading doses to allow all participants to receive BIVV009 while maintaining Part A blinding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIVV009</intervention_name>
    <description>BIVV009 will be administered by IV.</description>
    <arm_group_label>Part A: BIVV009 or Placebo</arm_group_label>
    <arm_group_label>Part B: Response Extension Phase (BIVV009)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered by IV.</description>
    <arm_group_label>Part A: BIVV009 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight of greater than or equal to (&gt;=) 39 kilogram (kg) at Screening

          -  Confirmed diagnosis of primary cold agglutinin disease (CAgD) based on the following
             criteria: a) Chronic hemolysis, b) Polyspecific direct antiglobulin test (DAT)
             positive, c) Monospecific DAT strongly positive for C3d, d) Cold agglutinin titer &gt;=
             64 at 4 degree Celsius, and e) Immunoglobulin G (IgG) DAT less than or equal to (&lt;=)
             1+, and, f) No overt malignant disease

          -  Hemoglobin level &lt;= 10.0 gram per deciliter (g/dL)

          -  Bilirubin level above the normal reference range

        Exclusion Criteria:

          -  Cold agglutinin syndrome secondary to infection, rheumatologic disease, or active
             hematologic malignancy

          -  Clinically relevant infection of any kind within the month preceding enrollment
             (example, active hepatitis C, pneumonia)

          -  Clinical diagnosis of systemic lupus erythematosus (SLE); or other autoimmune
             disorders with anti-nuclear antibodies at Screening

          -  Positive hepatitis panel (including hepatitis B surface antigen and/or hepatitis C
             virus antibody) prior to or at Screening

          -  Positive human immunodeficiency virus (HIV) antibody at Screening

          -  Treatment with rituximab monotherapy within 3 months or rituximab combination
             therapies (example, with bendamustine, fludarabine, ibrutinib, or cytotoxic drugs)
             within 6 months prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bioverativ Therapeutics Inc, Waltham, MA, USA</last_name>
    <phone>1-844-308-0808(US only)</phone>
    <email>clinicaltrials@bioverativ.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino, Study Coordinator</last_name>
      <phone>1 562-693-4477</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Dr. Richy Agajanian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Georgetown</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Jacobs, Study Coordinator</last_name>
      <phone>202-687-4868</phone>
      <email>jacobsh@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Dr. Catherine Broome</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Branch, Study Coordinator</last_name>
      <phone>1-844-308-0808</phone>
      <email>kebranch@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Elena Crouch</last_name>
      <email>ecrouch@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Irina Murakhovskaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College at Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saleha Batool</last_name>
      <phone>914-493-3045</phone>
      <email>Saleha_Batool@nymc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert G. Lerner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffanie Moore</last_name>
      <phone>252-744-1720</phone>
      <email>Mooreti15@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Dr. Darla Liles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Pasek, Study Coordinator</last_name>
      <phone>1-412-623-2697</phone>
      <email>pasekbb@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Dr. Joseph E. Kiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Ely</last_name>
      <phone>+43 1 40 400 29850</phone>
      <email>Sarah.Ely@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Dr Bernd Jilma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline De Man</last_name>
      <phone>+32 (0)3 217 74 48</phone>
      <email>caroline.deman@zna.be</email>
    </contact>
    <investigator>
      <last_name>Dr Ka Lung WU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Jolimont</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Pêtre</last_name>
      <phone>+32 (0)64 23 46 68</phone>
      <email>Helene.PETRE@jolimont.be</email>
    </contact>
    <investigator>
      <last_name>Dr Alain Kentos, Alain.KENTOS@jolimont.be</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Pannecoucke</last_name>
      <phone>+32 (0)16 34 15 74</phone>
      <email>Jill.pannecoucke@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Pr Daan Dierickx daan.dierickx@uzleuven.be</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adult Hematology Research</last_name>
      <phone>780-407-6090</phone>
    </contact>
    <investigator>
      <last_name>Dr. A. Peters, 780-407-1584 ext. 5</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämatologie-Onkologie</name>
      <address>
        <city>Dresden</city>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje van der Seylberg</last_name>
      <phone>+49 351 44 00022</phone>
      <email>a.vdseylberg@gokos-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Dr Thomas Illmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Preising</last_name>
      <phone>+49 201 723 4620</phone>
      <email>nicole.preising@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Dr Alexander Roeth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laniado Hospital</name>
      <address>
        <city>Netanya</city>
        <zip>4244916</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dikla Varsano</last_name>
      <phone>+972-9-8925248</phone>
      <email>dvarsano@laniado.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Aviv Avdi</last_name>
      <email>aavdi@laniado.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Dr Shlomo Bulvik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ela Shai</last_name>
      <phone>+972-5-05172903</phone>
      <email>elashai@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Yosef Kalish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia- Policlinico &quot;A. Gemelli&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lissandrini</last_name>
      <phone>+39 444 753518</phone>
      <email>laura.lissandrini@corisveneto.it</email>
    </contact>
    <investigator>
      <last_name>Dr Eros di Bona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5053</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Bøtter Brevik</last_name>
      <phone>+4755975362</phone>
      <email>anita.botter-brevik@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Eikevåg</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr Tor Henrik Anderson Tvedt tor.henrik.anderson.tvedt@helse-bergen.no</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pr Geir Tjonnfjord gtjonnfj@ous-hf.no, 0047 23 07 07 13 0</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital, Avdeling for blodsykdommer</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Turid Neverdal Almvik</last_name>
      <phone>+4772925041</phone>
      <email>Turid.Neverdal.Almvik@stolav.no</email>
    </contact>
    <investigator>
      <last_name>Dr Henrik Hjort Hansen henrik.hjorth-hansen@ntnu.no</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Salcedo</last_name>
      <phone>+34 911 916 481</phone>
      <email>isabel.salcedo@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Dr Jose Luis Bueno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinci i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Joan Cid jcid@clinic.cat, +34 932 275 448</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Roncel</last_name>
      <phone>+34 955 013 277</phone>
      <email>rocioroncel.ensayos.huvr@gmail.com</email>
    </contact>
    <contact_backup>
      <email>jesusms79@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr Jesus Martin Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ivars</last_name>
      <phone>+34 961 622 536</phone>
      <email>david.ivars@uv.es</email>
    </contact>
    <investigator>
      <last_name>Dr Miguel Fernandez Zarzoso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agglutinins</mesh_term>
    <mesh_term>Cold agglutinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

